Baseline and Early Treatment MRI Model for Predicting Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy in Patients With Triple-Negative Breast Cancer
American Journal of Roentgenology · 2025-11 · 225 (5)
DOI: 10.2214/ajr.25.33178 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Roentgenology, 2025-11. Verfasst von Bin Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 51008…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Magnetic Resonance Imaging, Neoadjuvant Therapy, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND. Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype lacking targeted therapies. Neoadjuvant chemoimmunotherapy (NACI) improves pathologic complete response (pCR) rates, although patient selection is challenging. OBJECTIVE. The purpose of the study was to develop and test a model incorporating baseline and early-treatment MRI features, including dynamic contrast enhancement (DCE) features, for predicting pCR in patients with TNBC undergoing NACI. METHODS. This retrospective study included patients with TNBC undergoing NACI who underwent breast MRI examinations, including DCE sequences, before treatment and after the first treatment cycle (i.e., early NACI) from a single-center training set of 90 women (mean age, 49 years; January 2018 to September 2024) and an external test set of 29 women (mean age, 46 years; date range unavailable) from publicly available trial data. Two radiologists evaluated the MRI features including percentage enhancement (PE) reduction, representing a semiquantitative assessment of relative expansion of intralesional nonenhancing components after early NACI. A model for predicting pCR on definitive surgery after NACI completion was constructed in the training set using independent predictors from multivariable logistic regression analysis and was evaluated in the external test set. Shapley additive explanations (SHAP) analysis was used to identify features' contributions to model predictions in the training set. RESULTS. Independent predictors of pCR in the training set were tumor unifocality (OR = 7.2, p = .001) on pretreatment MRI and early tumor shrinkage (ETS) of 37% or greater (OR = 9.7, p < .001) and PE reduction (OR = 9.7, p < .001) on early-NACI MRI. A model incorporating these parameters achieved in the external test set an AUC of 0.88, sensitivity of 74%, and specificity of 90% for predicting pCR. In the external test set, calibration curves showed strong concordance between model-predicted and observed pCR outcomes, and the Hosmer-Lemeshow test showed satisfactory model fit (p = .67). In the SHAP analysis, the global importance for model predictions was highest for PE reduction (mean absolute SHAP value, 0.286), followed by ETS (mean absolute SHAP value, 0.233) and unifocality (mean absolute SHAP value, 0.228). CONCLUSION. A clinically practical model was created for early pCR prediction in patients undergoing NACI for TNBC. CLINICAL IMPACT. This MRI-based predictive model could facilitate timely tailoring of clinical regimens after immunotherapy initiation by informing optimal deescalation strategies for responders while prompting therapeutic adaptations for nonresponders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, China.
- Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zitieren
APA
Liu, B., Wu, L., Liu, C., Long, X., Hu, S., Zhang, L., Liu, Z., & Liang, C. (2025). Baseline and Early Treatment MRI Model for Predicting Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy in Patients With Triple-Negative Breast Cancer. American Journal of Roentgenology, 225(5). https://doi.org/10.2214/ajr.25.33178
Vancouver
Liu B, Wu L, Liu C, Long X, Hu S, Zhang L, et al. Baseline and Early Treatment MRI Model for Predicting Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy in Patients With Triple-Negative Breast Cancer. American Journal of Roentgenology. 2025;225(5). doi:10.2214/ajr.25.33178
BibTeX
@article{Liu2025,
author = {Liu, Bin and Wu, Lei and Liu, Chunling and Long, Xiaoyu and Hu, Shan and Zhang, Linyu and Liu, Zaiyi and Liang, Changhong},
title = {Baseline and Early Treatment MRI Model for Predicting Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy in Patients With Triple-Negative Breast Cancer},
journal = {American Journal of Roentgenology},
year = {2025},
volume = {225},
number = {5},
doi = {10.2214/ajr.25.33178}
}
EUVIMED